Not exact matches
The
study notes that by adding the oral
cholera vaccine (OCV) to the picture — and achieving a 20 percent coverage rate within five years — the number of cases averted could rise to 88,974.
The
cholera studies led to the scuttling of a leading
vaccine candidate, a finer understanding of effective immune responses, and, ultimately, compelling evidence that a different
cholera vaccine worked.
Forty years ago Levine was one of a tiny cadre of researchers doing so - called human challenge
studies — intentionally infecting people with V.
cholerae and other pathogens to test drugs and
vaccines.
A
study published in PLOS NTDs examining the immune response to one of them in Haitian adults finds that while the first
vaccine round elicits a strong
cholera - specific response in the mucosa (the first point of contact with the
cholera pathogen), the booster dose after 2 weeks does not appear to stimulate the immune system further.
Jason Harris, from Massachusetts General Hospital in Boston, USA, and colleagues are
studying a bivalent whole cell oral (BivWC)
cholera vaccine produced in India that received pre-approval by WHO in 2011.
Given similar results from
studies of a different oral
cholera vaccine in Asia, the researchers argue that «additional evaluation of the optimal dosing schedule for oral
cholera vaccines with the goal of improving long - term immunity is warranted.»